The platform retained high sensitivity after exposure to plasma for more than one month, opening up a range of potential diagnostic applications, the researchers said.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
Comments from Quest suggest lab buys are becoming more complex while others suggest hospitals will remain reluctant to sell so long as premium pricing persists.
The company has seen a sharp rise in test revenues but still struggles with poor stock performance and could soon see new competition for OVA1.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.
The firm said it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.
The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.
The test will now be considered medically reasonable and necessary for patients over 45 with moderately elevated levels of prostate-specific antigen.